These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply. Labenz C; Schattenberg JM Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1318-1319. PubMed ID: 30488630 [No Abstract] [Full Text] [Related]
5. Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight. Authors' reply. Ajmera V Aliment Pharmacol Ther; 2023 May; 57(10):1168-1169. PubMed ID: 37094321 [No Abstract] [Full Text] [Related]
6. Editorial: NAFLD in Asia-clinical associations with advanced disease become clearer. Authors' reply. Chan WK; Dan YY; Wong VW; Aliment Pharmacol Ther; 2018 Apr; 47(7):1037-1038. PubMed ID: 29512909 [No Abstract] [Full Text] [Related]
7. Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations. Troisi J; Pierri L; Landolfi A; Marciano F; Bisogno A; Belmonte F; Palladino C; Guercio Nuzio S; Campiglia P; Vajro P Nutrients; 2017 May; 9(5):. PubMed ID: 28492501 [TBL] [Abstract][Full Text] [Related]
8. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis. Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208 [TBL] [Abstract][Full Text] [Related]
9. Editorial: further evidence for the use of advanced magnetic resonance imaging techniques to monitor NAFLD - authors' reply. Lin SC; Loomba R Aliment Pharmacol Ther; 2017 May; 45(9):1271-1272. PubMed ID: 28370055 [No Abstract] [Full Text] [Related]
10. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply. Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC Aliment Pharmacol Ther; 2020 Jun; 51(11):1200-1201. PubMed ID: 32424927 [No Abstract] [Full Text] [Related]
11. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876 [TBL] [Abstract][Full Text] [Related]
12. Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development. Xu Y; Han J; Dong J; Fan X; Cai Y; Li J; Wang T; Zhou J; Shang J Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862046 [TBL] [Abstract][Full Text] [Related]
13. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach. Feldman A; Eder SK; Felder TK; Paulweber B; Zandanell S; Stechemesser L; Schranz M; Strebinger G; Huber-Schönauer U; Niederseer D; Patsch W; Weghuber D; Tevini J; Datz C; Aigner E Diabetes Metab; 2019 Apr; 45(2):132-139. PubMed ID: 30266576 [TBL] [Abstract][Full Text] [Related]
14. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution. Tana C; Tana M; Rossi S; Silingardi M; Schiavone C J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163 [TBL] [Abstract][Full Text] [Related]
15. Editorial: collagen proportionate area as a prognostic indicator in NAFLD-authors' reply. Buzzetti E; Tsochatzis EA Aliment Pharmacol Ther; 2019 Jun; 49(11):1454-1455. PubMed ID: 31074896 [No Abstract] [Full Text] [Related]
16. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. Stål P World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963 [TBL] [Abstract][Full Text] [Related]
17. Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD-Authors' reply. Younossi ZM; Henry L Aliment Pharmacol Ther; 2020 Aug; 52(4):712. PubMed ID: 32886382 [No Abstract] [Full Text] [Related]
18. Editorial: NAFLD in HIV infection--call for action. Authors' reply. Vodkin I; Loomba R Aliment Pharmacol Ther; 2015 Mar; 41(6):591. PubMed ID: 25659210 [No Abstract] [Full Text] [Related]
19. Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Kang MK; Park JG; Kim MC Yonsei Med J; 2020 Oct; 61(10):860-867. PubMed ID: 32975060 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]